Several countries face challenges with lung cancer screening programs. A few examples of population-based Australian screening programs are "BreastScreen," the "National Bowel Cancer Screening Program," and the "National Cervical Screening Program."
On behalf of the Ministry of Health, the RIVM Center for Population Screening (RIVM-CvB) leads and manages the National Population Screening Programme; under which all Dutch citizens are invited, at a certain point in their lives, to participate in one of the national screening programs. The State begins, sets up, and finances three cancer population screening programs.
Therefore, there is a crucial requirement for a well-structured program such as a community-based program or a shared, informed decision-making program between clinicians and potential participants; accredited reporting centers; and a central data registry for quality control, monitoring, and outcome reporting. Additionally, integrated smoking cessation intervention, international data supporting cost-effectiveness, additional mortality benefits, and a high sustainability rate are a few factors that must be studied for lung cancer screening. Further, the International Association for the Study of Lung Cancer recommends implementing feasibility screening programs in the countries of Asia Pacific without participating in lung cancer screening studies. These programs involve smoking cessation initiatives, standardized algorithms for selecting and managing screening participants, and specialist multidisciplinary teams to manage participants with positive screening results. Therefore, the implementation of structured lung cancer screening programs is expected to be a lucrative opportunity in the lung cancer screening market during the forecast period.
The Asia Pacific lung cancer screening market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. The regional growth is attributed to various factors, such as the increasing incidence of lung cancer and growing prevalence of cigarette smoking among people. Also, rising government support for screening has led to the further growth of the market.
Asia Pacific Lung Cancer Screening Market Segmentation
The Asia Pacific lung cancer screening market is segmented into cancer type, technology, age group, end user, and country.
Based on cancer type, the Asia Pacific lung cancer screening market is segmented into Non–Small Cell Lung Cancer (NSCLC), and Small Cell Lung Cancer. The non–small cell lung cancer (NSCLC) segment held a larger share of the Asia Pacific lung cancer screening market in 2022.
Based on technology, the Asia Pacific lung cancer screening market is segmented into chest x-ray, low dose computed tomography (LDCT), liquid biopsy, and others. Chest x-ray segment held the largest share of the Asia Pacific lung cancer screening market in 2022.
Based on age group, the Asia Pacific lung cancer screening market is segmented into 50 and older, and below 50. 50 and older segment held the larger share of the Asia Pacific lung cancer screening market in 2022.
Based on end user, the Asia Pacific lung cancer screening market is segmented into hospital, diagnostic centre, and others. Hospital segment held the largest share of the Asia Pacific lung cancer screening market in 2022.
Based on country, the Asia Pacific Lung Cancer Screening Market is segmented into China Japan, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific lung cancer screening market in 2022.
Intelerad Medical Systems Incorporated, Nuance Communications Inc, GE HealthCare Technologies Inc, Medtronic Plc, Canon Medical Systems Corp, Koninklijke Philips NV, and Siemens AG are some of the leading companies operating in the Asia Pacific lung cancer screening market.
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 711.20 Million |
| Market Size by 2030 | US$ 1,362.43 Million |
| CAGR (2022 - 2030) | 8.5% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2030 |
| Segments Covered |
By Cancer Type
|
| Regions and Countries Covered |
Asia-Pacific
|
| Market leaders and key company profiles |
|
The Asia Pacific Lung Cancer Screening Market is valued at US$ 711.20 Million in 2022, it is projected to reach US$ 1,362.43 Million by 2030.
As per our report Asia Pacific Lung Cancer Screening Market, the market size is valued at US$ 711.20 Million in 2022, projecting it to reach US$ 1,362.43 Million by 2030. This translates to a CAGR of approximately 8.5% during the forecast period.
The Asia Pacific Lung Cancer Screening Market report typically cover these key segments-
The historic period, base year, and forecast period can vary slightly depending on the specific market research report. However, for the Asia Pacific Lung Cancer Screening Market report:
The Asia Pacific Lung Cancer Screening Market is populated by several key players, each contributing to its growth and innovation. Some of the major players include:
The Asia Pacific Lung Cancer Screening Market report is valuable for diverse stakeholders, including:
Essentially, anyone involved in or considering involvement in the Asia Pacific Lung Cancer Screening Market value chain can benefit from the information contained in a comprehensive market report.
Please tell us your area of interest
(Market Segments/ Regions and Countries/ Companies)
E 1803, Panchshil Towers,
Wagholi, Haveli,
Pune - 412207,
Maharashtra, India
US:+16467917070
sales@businessmarketinsights.com
Get Free Sample For Asia Pacific Lung Cancer Screening Market
